90Y radioembolization after radiation exposure from peptide receptor radionuclide therapy

Journal of Nuclear Medicine

Volumn 53, Issue 11, 2012, Pages 1663-1669

  Ezziddin, Samer ^a   Meyer, Carsten ^a   Kahancova, Stanislawa ^a   Haslerud, Torjan ^a   Willinek, Winfried ^a   Wilhelm, Kai ^a   Biersack, Hans Jürgen ^a   Ahmadzadehfar, Hojjat ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

177Lu DOTA octreotate; 90Y microspheres; Neuroendocrine tumors; Peptide receptor radionuclide therapy; Radioembolization

Indexed keywords

ANTINEOPLASTIC AGENT; KI 67 ANTIGEN; MICROSPHERE Y 90; RADIOACTIVE MICROSPHERE; RADIOISOTOPE; TETRAXETAN OCTREOTATE LU 177; UNCLASSIFIED DRUG; RECEPTOR; YTTRIUM;

ABDOMINAL PAIN; ADULT; ARTICLE; ARTIFICIAL EMBOLISM; ASCITES; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL ARTICLE; COHORT ANALYSIS; DUODENUM ULCER; FATIGUE; FEVER; HUMAN; LIVER METASTASIS; LIVER RESECTION; LIVER TOXICITY; NAUSEA; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PEPTIDE RECEPTOR RADIONUCLIDE THERAPY; PRIORITY JOURNAL; RADIATION EXPOSURE; RADIOACTIVITY; RADIOEMBOLIZATION; RADIOFREQUENCY ABLATION; RADIOISOTOPE THERAPY; RETROSPECTIVE STUDY; SALVAGE THERAPY; TREATMENT RESPONSE; TUMOR GROWTH; VOMITING; ANALYSIS OF VARIANCE; FEMALE; LIVER TUMOR; MALE; METABOLISM; METASTASIS; METHODOLOGY; MIDDLE AGED; PATHOLOGY;

ANALYSIS OF VARIANCE; EMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; RECEPTORS, PEPTIDE; RETROSPECTIVE STUDIES; SALVAGE THERAPY; YTTRIUM RADIOISOTOPES;

EID: 84868328386     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.107482     Document Type: Article

References (40)

1. Kwekkeboom DJ, Kam BL, van Essen M, et al. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer. 2010;17:R53-R73.
2. Pavel M, Baudin E, Couvelard A, et al. ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95:157-176.
3. Kam BL, Teunissen JJ, Krenning EP, et al. Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012;39(suppl 1):S103-S112.
4. Ahmadzadehfar H, Biersack HJ, Ezziddin S. Radioembolization of liver tumors with yttrium-90 microspheres. Semin Nucl Med. 2010;40:105-121.
5. 90Y microspheres) into current treatment options for liver tumors: introduction to the international working group report. Am J Clin Oncol. 2012;35:81-90.
6. Riaz A, Lewandowski RJ, Kulik LM, et al. Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review. J Vasc Interv Radiol. 2009;20:1121-1130, quiz 1131.
7. 90Y- microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys. 2009;74:1494-1500.
8. Young JY, Rhee TK, Atassi B, et al. Radiation dose limits and liver toxicities resulting from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma. J Vasc Interv Radiol. 2007;18:1375-1382.
9. Piana PM, Gonsalves CF, Sato T, et al. Toxicities after radioembolization with yttrium-90 SIR-spheres: incidence and contributing risk factors at a single center. J Vasc Interv Radiol. 2011;22:1373-1379.
10. Sangro B, Gil-Alzugaray B, Rodriguez J, et al. Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer. 2008;112:1538-1546.
11. 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: technical and methodologic considerations. J Vasc Interv Radiol. 2006;17:1251-1278.
12. Atwell TD, Charboneau JW, Que FG, et al. Treatment of neuroendocrine cancer metastatic to the liver: the role of ablative techniques. Cardiovasc Intervent Radiol. 2005;28:409-421.
13. Steward MJ, Warbey VS, Malhotra A, Caplin ME, Buscombe JR, Yu D. Neuroendocrine tumors: role of interventional radiology in therapy. Radiographics. 2008;28:1131-1145.
14. Saxena A, Chua TC, Bester L, Kokandi A, Morris DL. Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: a critical appraisal of 48 cases. Ann Surg. 2010;251: 910-916.
15. 90Y- microspheres: early results in 148 patients. Am J Clin Oncol. 2008;31:271-279.
16. 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg. 2008;247:1029-1035.
17. Kalinowski M, Dressler M, Konig A, et al. Selective internal radiotherapy with Yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: a prospective single center study. Digestion. 2009;79:137-142.
18. Cao CQ, Yan TD, Bester L, Liauw W, Morris DL. Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases. Br J Surg. 2010;97:537-543.
19. King J, Quinn R, Glenn DM, et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer. 2008;113: 921-929.
20. Paprottka PM, Hoffmann RT, Haug A, et al. Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres. Cardiovasc Intervent Radiol. 2012;35:334-342.
21. Memon K, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes. Int J Radiat Oncol Biol Phys. 2012;83:887-894.
22. Murthy R, Kamat P, Nunez R, et al. Yttrium-90 microsphere radioembolotherapy of hepatic metastatic neuroendocrine carcinomas after hepatic arterial embolization. J Vasc Interv Radiol. 2008;19:145-151.
23. Kennedy A, Nag S, Salem R, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys. 2007;68:13-23.
24. Giammarile F, Bodei L, Chiesa C, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging. 2011;38:1393-1406.
25. Ezziddin S, Opitz M, Attassi M, et al. Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2011;38:459-466.
26. 177Lu-octreotate. J Nucl Med. 2011;52:1197-1203.
27. 177Lu at high specific activities. Eur J Nucl Med Mol Imaging. 2003;30:917-920.
28. 177Lu-DOTA0,Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity. Eur J Nucl Med Mol Imaging. 2003;30:312-315.
29. 177Lu-DOTA(0),Tyr3]octreotate. Eur J Nucl Med Mol Imaging. 2003; 30:417-422.
30. 177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005;23:2754-2762.
31. Kwekkeboom DJ, Krenning EP, Lebtahi R, et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology. 2009;90: 220-226.
32. Bodei L, Cremonesi M, Grana CM, et al. Yttrium-labelled peptides for therapy of NET. Eur J Nucl Med Mol Imaging. 2012;39(suppl 1):S93-S102.
33. Cremonesi M, Botta F, Di Dia A, et al. Dosimetry for treatment with radiolabelled somatostatin analogues. A review. Q J Nucl Med Mol Imaging. 2010; 54:37-51.
34. 111In-DTPAo]octreotide in patients. Eur J Nucl Med. 2001; 28:1319-1325.
35. 177Lu-DOTA-D-Phe (1)-Tyr (3)-octreotate. Eur J Nucl Med Mol Imaging. 2010;37:212-225.
36. 111In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2004;31:1257-1262.
37. 111In-pentetreotide in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2004; 31:1386-1392.
38. 111In- DTPA-octreotide. Eur J Nucl Med. 2001;28:1743-1750.
39. Cremonesi M, Ferrari M, Bodei L, Tosi G, Paganelli G. Dosimetry in peptide radionuclide receptor therapy: a review. J Nucl Med. 2006;47:1467-1475.
40. 90Ymicrospheres: dosimetric and radiobiological investigation for multi-cycle treatment. Eur J Nucl Med Mol Imaging. 2008;35:2088-2096.